A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
Phase of Trial: Phase I/II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs BCG vaccine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2017 Planned End Date changed from 1 Oct 2023 to 31 Dec 2022.
- 25 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 30 Oct 2019.
- 15 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.